CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? - Wikidata - awgldk - TriplyDB

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

http://www.wikidata.org/entity/Q34810458

about

Contribution of CXCL12 secretion to invasion of breast cancer cells.Molecular mechanisms of peritoneal dissemination in gastric cancer Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer Tumor refractoriness to anti-VEGF therapy The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance Optimal combination of antiangiogenic therapy for hepatocellular carcinoma A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting CXCL12 chemokine and GABA neurotransmitter systems crosstalk and their putative roles Endothelial tip cells in ocular angiogenesis: potential target for anti-angiogenesis therapy Pharmacological inhibition of feline immunodeficiency virus (FIV)Tumor stroma as targets for cancer therapy Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Expression of the chemokine receptor CXCR7 in CXCR4-expressing human 143B osteosarcoma cells enhances lung metastasis of intratibial xenografts in SCID mice Dynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel density A multi-targeted approach to suppress tumor-promoting inflammation RNA plasticity and selectivity applicable to therapeutics and novel biosensor development Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)Molecular mechanisms and clinical applications of angiogenesis Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.Normalization of the vasculature for treatment of cancer and other diseases.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Elucidating a key component of cancer metastasis: CXCL12 (SDF-1α) binding to CXCR4.Secreted CXCL12 (SDF-1) forms dimers under physiological conditions.CXCL12 and [N33A]CXCL12 in 5637 and HeLa cells: regulating HER1 phosphorylation via calmodulin/calcineurin.Immunological effects of vaccines combined with granulocyte colony-stimulating factor on a murine WEHI-3 leukemia model.CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism Quantitative phosphoproteomics of CXCL12 (SDF-1) signaling.Stromal cell-derived factor-1 overexpression induces gastric dysplasia through expansion of stromal myofibroblasts and epithelial progenitors.A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer(1,2.)Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development.Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.Differential expression of SDF-1 isoforms in bladder cancer A systems biology approach to the global analysis of transcription factors in colorectal cancer.CD133+ and Nestin+ Glioma Stem-Like Cells Reside Around CD31+ Arterioles in Niches that Express SDF-1α, CXCR4, Osteopontin and Cathepsin K.

P2860

Q22000754-3A835A0F-85E5-4B1D-B1F5-7BA2F2DEE704 Q26738538-353EFEFF-ECD3-4DB7-9712-58C6CAF7E366 Q26741064-AE7B6FE6-C95A-4429-9259-13E7DB4CC97C Q26747678-2C7373A7-DFAB-4528-8659-576454717BF4 Q26748194-29606B63-B7C7-46F6-AA09-355178F81805 Q26765869-813B7B2E-5386-4B49-BDA9-22F3C1A068A7 Q26799458-613DCD83-157A-471B-8D12-BF17EA40E7BF Q26800288-8B73AE4F-2296-47AB-945E-F70B4C3E6AEE Q26823035-64DB6C7E-A500-4D24-99A6-C8051199F4FF Q26830743-C12A6278-088A-4C6A-8807-C527C08236E4 Q26849606-B7B3F581-5EF7-4CE7-A78C-B81A049E9442 Q26859215-E3D76334-591F-4EAD-B9D6-05AAFDCD18DE Q26865091-4A981C42-06EF-4736-9273-1C77180AE1A1 Q26995310-C603951B-F711-44E4-80D7-928B90EF5BC2 Q27015980-27688B3F-9157-49DC-8F95-101A1872DE04 Q27021470-1522DA64-E349-4F97-AC98-91604DE6BB03 Q27307103-E99E2048-9315-424C-9040-09EE27A32FF3 Q27308856-6BC0A0A4-2223-434C-975E-327A01DC3F56 Q28393278-30B27645-D419-4217-9B65-6C6F66697793 Q28727743-186F4E31-C1EB-45E7-B11D-3264DD62C2FE Q28732214-9D0838DF-276B-4CA4-9008-A0D7FB15812F Q29547314-F4287F04-F512-4F04-A52D-FDF566294CEA Q30399006-70BE2F17-2C2E-460D-B972-762B33A86502 Q30434521-B27C9A2A-A6B1-4B36-AB09-7076A3F9B34F Q30471456-3F415202-D79F-46EF-BEE5-4B6EDB9DE6BA Q30542073-6F58D27D-34E1-4345-89A8-AD6E86940221 Q30577284-D265D8D8-191A-47A3-B5F7-D40030AA0392 Q30647478-0DCB45A0-63D8-4D99-8E8A-3AA7A4648D83 Q31056366-54C37992-60E8-4537-84B8-366949B676F7 Q33597774-B4435A59-C1F6-47BE-A8D9-30CE97EDD9E0 Q33677057-51725B3E-A4F6-4788-B519-1DAB55A38E40 Q33913982-ECC4A763-3A1B-4F6A-82AF-345F78BBF860 Q34031600-8704E9BB-5E4D-4730-8AD0-842F94540E60 Q34061016-3DC87B6A-5E65-442E-B369-6DB53F5F51EA Q34092009-FD8A494D-8243-40DB-8076-AF4FD5C5135B Q34199625-BEFB9427-A5E7-4AA1-8492-9781CC9B6F1A Q34231598-D14A4805-5468-4E76-A71B-B5D2A7E84C5F Q34342390-AD4BB8A5-72B7-4F7E-9876-001A667C9153 Q34361370-422068DA-7826-4385-99D5-46556A88224A Q34468655-A3078DD6-93E5-4B93-A78F-9D4787E25EF3

P2860

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

http://www.wikidata.org/entity/Q34810458

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

CXCL12 (SDF1alpha)-CXCR4/CXCR7 ...... izer for anticancer therapies?

@ast

CXCL12 (SDF1alpha)-CXCR4/CXCR7 ...... izer for anticancer therapies?

@en

CXCL12

@nl

type

label

CXCL12 (SDF1alpha)-CXCR4/CXCR7 ...... izer for anticancer therapies?

@ast

CXCL12 (SDF1alpha)-CXCR4/CXCR7 ...... izer for anticancer therapies?

@en

CXCL12

@nl

prefLabel

CXCL12 (SDF1alpha)-CXCR4/CXCR7 ...... izer for anticancer therapies?

@ast

CXCL12 (SDF1alpha)-CXCR4/CXCR7 ...... izer for anticancer therapies?

@en

CXCL12

@nl

P1433

Q34810458-FAB6B609-45A4-4BBC-891D-9E80DC9A589D

P1476

Q34810458-38524383-E5DB-4408-B37C-B46DF11395F1

P2093

Q34810458-1424B102-0E0B-41A2-9EC0-9A8DAA79095E

Q34810458-1AE251E1-EC62-43F7-86D7-CF8ED6DD9A28

Q34810458-3EF42940-8C95-414B-BBE4-4479F69B8438

Q34810458-44CB104F-450C-49B0-8ECD-079178BA6C0D

Q34810458-56AE005C-C434-475C-8ED0-70535F9A3F46

Q34810458-A6CB9355-0730-4F77-A749-33EBD52834DB

P2860

Q34810458-008BF7CD-DED0-4FD2-B44E-3E376868A64D

Q34810458-03746020-7574-4E98-BA43-7D058705551E

Q34810458-042A45B1-1487-4909-BFB4-94AF50FDC1FB

Q34810458-04D59A2F-8A86-4046-ACC6-C5D43879CBFA

Q34810458-070F0610-99C6-4BE9-80F4-83C63E2CA77B

Q34810458-07929F52-84EF-48DA-AE09-EF8AF6057DB6

Q34810458-0ABC5B09-B909-444C-89E7-900D95B91A72

Q34810458-0C944D82-C777-4FEB-BBD3-6B161D3824D4

Q34810458-129DBB4A-089B-4157-B756-BA277FCEC19E

Q34810458-17AE6635-67B1-4185-8ABE-31D720892ED2

P304

Q34810458-52B4DD00-7BD5-411A-B5ED-639512FF41D2

P31

Q34810458-12D69D9A-DAEB-4CBF-BB64-F46D9A2A01B8

P356

Q34810458-0164EA81-E53D-4D4F-B2B9-92E2C42E1AE2

P407

Q34810458-5DFC5ADC-29AF-4EBE-9AC5-25476552B740

P433

Q34810458-C5760B3D-C899-4C8E-8D39-09A314BB02AD

P478

Q34810458-109B4AE7-F949-46B1-8DD5-FF4AA602A021

P577

Q34810458-9CD93F37-1263-4688-A558-76B7CAD1EC13

P5875

Q34810458-092363EC-BAD6-483E-90BC-E36CA9531D92

P698

Q34810458-780F59D2-4844-49F3-A8B3-84AA5833DB0D

P932

Q34810458-E8EE0B6F-7E05-4F75-BA5B-D15B9CF047B3

P356

1078-0432.CCR-10-2636

P1433

Clinical Cancer Research

P1476

CXCL12 (SDF1alpha)-CXCR4/CXCR7 ...... izer for anticancer therapies?

@en

P2093

Dai Fukumura

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

Lei Xu

http://www.w3.org/2001/XMLSchema#string

Nathaniel D Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

Rakesh K Jain

http://www.w3.org/2001/XMLSchema#string

Sergey V Kozin

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of chemokine receptors in breast cancer metastasis

The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Sorafenib in advanced hepatocellular carcinoma

CCL27-CCR10 interactions regulate T cell-mediated skin inflammation

AMD3100 is a CXCR7 ligand with allosteric agonist properties

The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes

Control of chemokine-guided cell migration by ligand sequestration

P304

2074-2080

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-2636

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50196053

http://www.w3.org/2001/XMLSchema#string

P698

21349998

http://www.w3.org/2001/XMLSchema#string

P932

3079023

http://www.w3.org/2001/XMLSchema#string